Creative Planning reduced its stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 18.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,068 shares of the biopharmaceutical company's stock after selling 1,556 shares during the quarter. Creative Planning's holdings in Horizon Therapeutics Public were worth $437,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HZNP. Samalin Investment Counsel LLC acquired a new position in Horizon Therapeutics Public during the first quarter worth about $41,000. CoreCap Advisors LLC acquired a new position in shares of Horizon Therapeutics Public in the second quarter valued at approximately $33,000. Allworth Financial LP raised its position in shares of Horizon Therapeutics Public by 936.7% in the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 562 shares during the last quarter. Stonebridge Capital Advisors LLC raised its position in shares of Horizon Therapeutics Public by 550.0% in the first quarter. Stonebridge Capital Advisors LLC now owns 650 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 550 shares during the last quarter. Finally, Covestor Ltd raised its position in shares of Horizon Therapeutics Public by 152.9% in the first quarter. Covestor Ltd now owns 860 shares of the biopharmaceutical company's stock valued at $91,000 after buying an additional 520 shares during the last quarter. 91.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HZNP has been the subject of a number of analyst reports. BMO Capital Markets lowered shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating in a research report on Tuesday, December 13th. SVB Leerink lowered shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating and upped their price target for the stock from $88.00 to $116.50 in a research report on Tuesday, December 13th. Wells Fargo & Company lowered shares of Horizon Therapeutics Public from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $118.00 to $116.50 in a research report on Monday, December 12th. TheStreet raised shares of Horizon Therapeutics Public from a "c+" rating to a "b-" rating in a research report on Tuesday, November 22nd. Finally, HC Wainwright began coverage on shares of Horizon Therapeutics Public in a research note on Tuesday, November 1st. They set a "neutral" rating and a $74.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $111.42.

Insider Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Price Performance

NASDAQ HZNP opened at $109.68 on Friday. The company has a 50 day simple moving average of $109.07 and a 200-day simple moving average of $82.36. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.96 and a quick ratio of 3.74. The firm has a market capitalization of $24.86 billion, a price-to-earnings ratio of 44.95, a price-to-earnings-growth ratio of 1.70 and a beta of 1.15. Horizon Therapeutics Public Limited has a 52-week low of $57.84 and a 52-week high of $117.49.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.25. The firm had revenue of $925.36 million for the quarter, compared to analyst estimates of $888.93 million. Horizon Therapeutics Public had a net margin of 15.51% and a return on equity of 24.59%. Equities research analysts predict that Horizon Therapeutics Public Limited will post 4.23 earnings per share for the current fiscal year.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Recommended Stories

• Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.